{"id":68419,"date":"2026-06-17T21:01:12","date_gmt":"2026-06-17T13:01:12","guid":{"rendered":"https:\/\/flcube.com\/?p=68419"},"modified":"2026-06-17T21:01:13","modified_gmt":"2026-06-17T13:01:13","slug":"shanghai-henlius-biotech-receives-australian-clearance-for-phase-ii-study-of-pd-l1-adc-hlx43-combined-with-hansizhuang-in-nsclc-neoadjuvant-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68419","title":{"rendered":"Shanghai Henlius Biotech Receives Australian Clearance for Phase II Study of PD-L1 ADC HLX43 Combined with Hansizhuang in NSCLC Neoadjuvant Therapy"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Shanghai Henlius Biotech Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2696:HKG\">HKG: 2696<\/a>) announced it has received regulatory clearance in <strong>Australia<\/strong> to conduct a <strong>Phase II clinical study<\/strong> evaluating <strong>HLX43<\/strong>, the company&#8217;s <strong>PD-L1 antibody-drug conjugate (ADC)<\/strong>, in combination with <strong>Hansizhuang (serplulimab)<\/strong> as <strong>neoadjuvant therapy<\/strong> for <strong>non-small cell lung cancer (NSCLC)<\/strong>. The dual-mechanism approach combines immune checkpoint blockade with targeted cytotoxic payload delivery.<\/p>\n\n\n\n<h2 id=\"h-regulatory-amp-clinical-development-milestone\" class=\"wp-block-heading\">Regulatory &amp; Clinical Development Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Shanghai Henlius Biotech Inc. (HKG: 2696)<\/td><\/tr><tr><td><strong>Regulatory Jurisdiction<\/strong><\/td><td>Australia (Therapeutic Goods Administration)<\/td><\/tr><tr><td><strong>Trial Phase<\/strong><\/td><td>Phase II<\/td><\/tr><tr><td><strong>Study Design<\/strong><\/td><td>Combination therapy evaluation<\/td><\/tr><tr><td><strong>Primary Indication<\/strong><\/td><td>Non-small cell lung cancer (NSCLC)<\/td><\/tr><tr><td><strong>Treatment Setting<\/strong><\/td><td>Neoadjuvant therapy<\/td><\/tr><tr><td><strong>Combination Partners<\/strong><\/td><td>HLX43 (PD-L1 ADC) + Hansizhuang (anti-PD-1 monoclonal antibody)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-profiles-amp-mechanism-of-action\" class=\"wp-block-heading\">Product Profiles &amp; Mechanism of Action<\/h2>\n\n\n\n<h3 id=\"h-hlx43-pd-l1-antibody-drug-conjugate\" class=\"wp-block-heading\">HLX43 \u2013 PD-L1 Antibody-Drug Conjugate<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Classification:<\/strong> Potential best-in-class broad-spectrum anti-tumor PD-L1 ADC<\/li>\n\n\n\n<li><strong>Dual Mechanism:<\/strong> Combines immune checkpoint blockade with payload-mediated cytotoxicity<\/li>\n\n\n\n<li><strong>Clinical Activity:<\/strong> Monotherapy studies demonstrated encouraging anti-tumor activity in previously treated NSCLC patients<\/li>\n\n\n\n<li><strong>Patient Population:<\/strong> Effective irrespective of histology and PD-L1 expression levels<\/li>\n\n\n\n<li><strong>Safety Profile:<\/strong> Favorable safety and tolerability in early clinical studies<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-hansizhuang-serplulimab-anti-pd-1-monoclonal-antibody\" class=\"wp-block-heading\">Hansizhuang (serplulimab) \u2013 Anti-PD-1 Monoclonal Antibody<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Development Status:<\/strong> Independently developed by Henlius<\/li>\n\n\n\n<li><strong>Global Approval:<\/strong> Marketing authorization in 50 markets worldwide<\/li>\n\n\n\n<li><strong>Lung Cancer Coverage:<\/strong> Comprehensive first-line standard-of-care across key indications:<\/li>\n\n\n\n<li>Extensive-stage small cell lung cancer (ES-SCLC)<\/li>\n\n\n\n<li>Squamous non-small cell lung cancer (sqNSCLC)<\/li>\n\n\n\n<li>Non-squamous non-small cell lung cancer (nsqNSCLC)<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-rationale-amp-combination-synergy\" class=\"wp-block-heading\">Strategic Rationale &amp; Combination Synergy<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The combination leverages complementary mechanisms of action:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Immune Activation:<\/strong> Hansizhuang blocks PD-1 to enhance T-cell mediated anti-tumor immunity<\/li>\n\n\n\n<li><strong>Targeted Cytotoxicity:<\/strong> HLX43 delivers cytotoxic payload directly to PD-L1 expressing tumor cells<\/li>\n\n\n\n<li><strong>Neoadjuvant Setting:<\/strong> Early intervention may enhance pathologic complete response rates and improve surgical outcomes<\/li>\n\n\n\n<li><strong>Broad Applicability:<\/strong> HLX43&#8217;s activity independent of PD-L1 expression expands treatable patient population<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-competitive-landscape\" class=\"wp-block-heading\">Market Impact &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NSCLC Market Opportunity:<\/strong> Represents approximately 85% of all lung cancer cases with significant unmet need in neoadjuvant setting<\/li>\n\n\n\n<li><strong>ADC Innovation:<\/strong> PD-L1 targeting ADC represents novel therapeutic approach combining immunotherapy and targeted chemotherapy<\/li>\n\n\n\n<li><strong>Henlius Portfolio Strength:<\/strong> Demonstrates company&#8217;s ability to develop both innovative monotherapies and synergistic combinations<\/li>\n\n\n\n<li><strong>Global Strategy:<\/strong> Australian trial supports international development pathway and potential global registration strategy<\/li>\n\n\n\n<li><strong>Competitive Differentiation:<\/strong> Dual-mechanism approach may offer advantages over single-agent immunotherapy or conventional chemotherapy combinations<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-outlook\" class=\"wp-block-heading\">Strategic Outlook<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This Phase II study represents a strategic expansion of Henlius&#8217; oncology portfolio into the high-value ADC space while leveraging its established Hansizhuang franchise. The neoadjuvant setting offers potential for improved long-term outcomes in early-stage NSCLC, addressing a critical gap in current treatment paradigms. Success in this combination approach could position Henlius as a leader in next-generation immuno-oncology combinations, building on its strong foundation in monoclonal antibodies and expanding into the rapidly growing ADC market segment.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory pathways, and market opportunities. Actual results may differ due to clinical trial outcomes, regulatory decisions, competitive dynamics, and evolving treatment standards.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026061600911_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026061600911_c.\"><\/object><a id=\"wp-block-file--media-4b4d41f8-45f9-45d6-99d3-e44c4561f2b1\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026061600911_c.pdf\">2026061600911_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026061600911_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-4b4d41f8-45f9-45d6-99d3-e44c4561f2b1\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Henlius Biotech Inc. (HKG: 2696) announced it has received regulatory clearance in Australia to&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[35,62,29,270,18],"class_list":["post-68419","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-clinical-trial-approval-initiation","tag-combination-therapy","tag-henlius-biotech","tag-pd-1-l1"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shanghai Henlius Biotech Receives Australian Clearance for Phase II Study of PD-L1 ADC HLX43 Combined with Hansizhuang in NSCLC Neoadjuvant Therapy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Henlius Biotech Inc. (HKG: 2696) announced it has received regulatory clearance in Australia to conduct a Phase II clinical study evaluating HLX43, the company&#039;s PD-L1 antibody-drug conjugate (ADC), in combination with Hansizhuang (serplulimab) as neoadjuvant therapy for non-small cell lung cancer (NSCLC). The dual-mechanism approach combines immune checkpoint blockade with targeted cytotoxic payload delivery.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68419\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shanghai Henlius Biotech Receives Australian Clearance for Phase II Study of PD-L1 ADC HLX43 Combined with Hansizhuang in NSCLC Neoadjuvant Therapy\" \/>\n<meta property=\"og:description\" content=\"Shanghai Henlius Biotech Inc. (HKG: 2696) announced it has received regulatory clearance in Australia to conduct a Phase II clinical study evaluating HLX43, the company&#039;s PD-L1 antibody-drug conjugate (ADC), in combination with Hansizhuang (serplulimab) as neoadjuvant therapy for non-small cell lung cancer (NSCLC). The dual-mechanism approach combines immune checkpoint blockade with targeted cytotoxic payload delivery.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68419\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-17T13:01:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-17T13:01:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68419#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68419\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shanghai Henlius Biotech Receives Australian Clearance for Phase II Study of PD-L1 ADC HLX43 Combined with Hansizhuang in NSCLC Neoadjuvant Therapy\",\"datePublished\":\"2026-06-17T13:01:12+00:00\",\"dateModified\":\"2026-06-17T13:01:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68419\"},\"wordCount\":484,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Clinical trial approval \\\/ initiation\",\"Combination therapy\",\"Henlius Biotech\",\"PD-1\\\/L1\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68419#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68419\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68419\",\"name\":\"Shanghai Henlius Biotech Receives Australian Clearance for Phase II Study of PD-L1 ADC HLX43 Combined with Hansizhuang in NSCLC Neoadjuvant Therapy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-17T13:01:12+00:00\",\"dateModified\":\"2026-06-17T13:01:13+00:00\",\"description\":\"Shanghai Henlius Biotech Inc. (HKG: 2696) announced it has received regulatory clearance in Australia to conduct a Phase II clinical study evaluating HLX43, the company's PD-L1 antibody-drug conjugate (ADC), in combination with Hansizhuang (serplulimab) as neoadjuvant therapy for non-small cell lung cancer (NSCLC). The dual-mechanism approach combines immune checkpoint blockade with targeted cytotoxic payload delivery.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68419#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68419\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68419#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shanghai Henlius Biotech Receives Australian Clearance for Phase II Study of PD-L1 ADC HLX43 Combined with Hansizhuang in NSCLC Neoadjuvant Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shanghai Henlius Biotech Receives Australian Clearance for Phase II Study of PD-L1 ADC HLX43 Combined with Hansizhuang in NSCLC Neoadjuvant Therapy - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Henlius Biotech Inc. (HKG: 2696) announced it has received regulatory clearance in Australia to conduct a Phase II clinical study evaluating HLX43, the company's PD-L1 antibody-drug conjugate (ADC), in combination with Hansizhuang (serplulimab) as neoadjuvant therapy for non-small cell lung cancer (NSCLC). The dual-mechanism approach combines immune checkpoint blockade with targeted cytotoxic payload delivery.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68419","og_locale":"en_US","og_type":"article","og_title":"Shanghai Henlius Biotech Receives Australian Clearance for Phase II Study of PD-L1 ADC HLX43 Combined with Hansizhuang in NSCLC Neoadjuvant Therapy","og_description":"Shanghai Henlius Biotech Inc. (HKG: 2696) announced it has received regulatory clearance in Australia to conduct a Phase II clinical study evaluating HLX43, the company's PD-L1 antibody-drug conjugate (ADC), in combination with Hansizhuang (serplulimab) as neoadjuvant therapy for non-small cell lung cancer (NSCLC). The dual-mechanism approach combines immune checkpoint blockade with targeted cytotoxic payload delivery.","og_url":"https:\/\/flcube.com\/?p=68419","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-17T13:01:12+00:00","article_modified_time":"2026-06-17T13:01:13+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68419#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68419"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shanghai Henlius Biotech Receives Australian Clearance for Phase II Study of PD-L1 ADC HLX43 Combined with Hansizhuang in NSCLC Neoadjuvant Therapy","datePublished":"2026-06-17T13:01:12+00:00","dateModified":"2026-06-17T13:01:13+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68419"},"wordCount":484,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Clinical trial approval \/ initiation","Combination therapy","Henlius Biotech","PD-1\/L1"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68419#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68419","url":"https:\/\/flcube.com\/?p=68419","name":"Shanghai Henlius Biotech Receives Australian Clearance for Phase II Study of PD-L1 ADC HLX43 Combined with Hansizhuang in NSCLC Neoadjuvant Therapy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-17T13:01:12+00:00","dateModified":"2026-06-17T13:01:13+00:00","description":"Shanghai Henlius Biotech Inc. (HKG: 2696) announced it has received regulatory clearance in Australia to conduct a Phase II clinical study evaluating HLX43, the company's PD-L1 antibody-drug conjugate (ADC), in combination with Hansizhuang (serplulimab) as neoadjuvant therapy for non-small cell lung cancer (NSCLC). The dual-mechanism approach combines immune checkpoint blockade with targeted cytotoxic payload delivery.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68419#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68419"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68419#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shanghai Henlius Biotech Receives Australian Clearance for Phase II Study of PD-L1 ADC HLX43 Combined with Hansizhuang in NSCLC Neoadjuvant Therapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68419","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68419"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68419\/revisions"}],"predecessor-version":[{"id":68421,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68419\/revisions\/68421"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68419"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68419"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68419"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}